Fospropofol disodium + Fospropofol disodium + Placebo + Midazolam + Fentanyl
ApprovedTerminated 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Procedural Sedation
Conditions
Procedural Sedation, Regional Anesthesia Block, Orthopedic Surgery
Trial Timeline
Feb 1, 2011 → Mar 1, 2011
NCT ID
NCT01195103About Fospropofol disodium + Fospropofol disodium + Placebo + Midazolam + Fentanyl
Fospropofol disodium + Fospropofol disodium + Placebo + Midazolam + Fentanyl is a approved stage product being developed by Eisai for Procedural Sedation. The current trial status is terminated. This product is registered under clinical trial identifier NCT01195103. Target conditions include Procedural Sedation, Regional Anesthesia Block, Orthopedic Surgery.
Hype Score Breakdown
Clinical
20
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01195103 | Approved | Terminated |
Competing Products
2 competing products in Procedural Sedation
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AQUAVAN® (fospropofol disodium) Injection | Eisai | Phase 2/3 | 38 |
| Dexmedetomidine + Chloral hydrate | Pfizer | Phase 2 | 27 |